This article has Open Peer Review reports available.
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
© The Author(s). 2017
Received: 5 April 2016
Accepted: 14 March 2017
Published: 23 March 2017
Open Peer Review reports
Pre-publication versions of this article are available by contacting email@example.com.
|5 Apr 2016||Submitted||Original manuscript|
|1 Dec 2016||Reviewed||Reviewer Report - Todd Miller|
|27 Dec 2016||Author responded||Author comments - Seung Kim|
|Resubmission - Version 2|
|27 Dec 2016||Submitted||Manuscript version 2|
|29 Jan 2017||Author responded||Author comments - Seung Kim|
|Resubmission - Version 3|
|29 Jan 2017||Submitted||Manuscript version 3|
|4 Mar 2017||Author responded||Author comments - Seung Kim|
|Resubmission - Version 4|
|4 Mar 2017||Submitted||Manuscript version 4|
|14 Mar 2017||Editorially accepted|
|23 Mar 2017||Article published||10.1186/s12885-017-3196-6|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.